treatment of head and neck cancer Press Release

Title Picture
10/10/2018 - 21:00
CEL-SCI ANNOUNCES WARRANTS TO EXPIRE ON OCTOBER 11, 2018
Cel-Sci's picture
Cel-Sci
09/14/2018 - 04:39
CEL-SCI RECEIVES $5.4 MILLION FROM WARRANT EXERCISES
Cel-Sci's picture
Cel-Sci
09/05/2018 - 19:21
NIH SELECTS CEL-SCI's LEAPS RHEUMATOID ARTHRITIS VACCINE FOR COMMERCIALIZATION ACCELERATOR PROGRAM
Cel-Sci's picture
Cel-Sci
07/12/2018 - 23:40
CEL-SCI REPORTS ON NYSE AMERICAN NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN
Cel-Sci's picture
Cel-Sci
06/27/2018 - 15:10
CEL-SCI WINS BREACH OF CONTRACT RULING AGAINST CLINICAL RESEARCH ORGANIZATION INVENTIV, NOW KNOWN AS SYNEOS HEALTH
Cel-Sci's picture
Cel-Sci
06/08/2018 - 06:14
U.S. PATENT OFFICE ALLOWS NEW CEL-SCI PATENTS FOR LEAPS VACCINE PLATFORM TECHNOLOGY
Cel-Sci's picture
Cel-Sci
05/22/2018 - 05:13
CEL-SCI CORPORATION TO PRESENT AT THE 8TH ANNUAL LD MICRO INVITATIONAL
Cel-Sci's picture
Cel-Sci
05/02/2018 - 08:34
CEL-SCI CORPORATION ANNOUNCES UPCOMING INVESTOR CONFERENCE PRESENTATIONS
Cel-Sci's picture
Cel-Sci
04/17/2018 - 14:15
North Memorial Health, Delta Dental Partner to Host HPV-Associated Head and Neck Cancer Awareness Event
North Memorial Medical Center's picture
North Memorial ...
04/09/2018 - 05:34
CEL-SCI CORPORATION TO PRESENT AT THE MICROCAP CONFERENCE
Cel-Sci's picture
Cel-Sci
02/05/2018 - 15:21
CEL-SCI TO PRESENT AT 2018 BIO CEO & INVESTOR CONFERENCE
Cel-Sci's picture
Cel-Sci
01/30/2018 - 16:54
U.S. PATENT OFFICE ALLOWS NEW CEL-SCI PATENT FOR LEAPS VACCINE PLATFORM TECHNOLOGY
Cel-Sci's picture
Cel-Sci
01/16/2018 - 12:34
CEL-SCI ANNOUNCES ADJUSTMENT TO WARRANT EXERCISE PRICE
Cel-Sci's picture
Cel-Sci
01/08/2018 - 12:06
CEL-SCI AWARDED PATENT FOR LEAPS VACCINE IN TREATMENT OF RHEUMATOID ARTHRITIS
Cel-Sci's picture
Cel-Sci
12/29/2017 - 15:05
CEL-SCI REPORTS FISCAL 2017 FINANCIAL RESULTS AND CLINICAL & CORPORATE DEVELOPMENTS
Cel-Sci's picture
Cel-Sci
12/18/2017 - 16:18
CEL-SCI ANNOUNCES ROBERT WATSON JOINS ITS BOARD OF DIRECTORS
Cel-Sci's picture
Cel-Sci
12/11/2017 - 12:48
CEL-SCI REACHES FULL ENROLLMENT IN PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY
Cel-Sci's picture
Cel-Sci
06/06/2016 - 07:46
Pembrolizumab elicits significant anti-tumor activity in advanced head and neck cancer patients
Dana Farber's picture
Dana Farber
01/14/2016 - 08:58
CEL-SCI CORPORATION TO PRESENT AT THE NOBLE FINANCIAL CAPITAL MARKETS' 12TH ANNUAL INVESTOR CONFERENCE
Cel-Sci's picture
Cel-Sci